ADAM17 and cardiac hypertrophy: On the other hand, due to the structural and functional heterogeneity of ADAM17 substrates, the sheddase is also involved in various pathological processes such as cancer, inflammatory diseases, neurological diseases, cardiac failure, atherosclerosis, diabetes, cardiac hypertrophy, and hypertension (Sandgren et al., 1990; Black et al., 1997; Peschon et al., 1998; Li et al., 2006; Ohtsu et al., 2006b; Zhan et al., 2007; Wang et al., 2009; Scheller et al., 2011; Giricz et al., 2013; Menghini et al., 2013; Xia et al., 2013).